EX-99.1 2 aipg_ex991.htm PRESS RELEASE aipg_ex991.htm EXHIBIT 99.1 AI Technology Group Inc. PRESS RELEASE January 12, 2026 Ai Technology Group Inc. (the “Company”) and AVM Biotechnology Inc. (“AVM”, the Washington State company that is the subject of the proposed merger) provide this joint press release. The Company continues with the funding of their proposed merger with AVM on an exclusive basis and announces we are in the process of extending funding dates to accommodate extended merger and financial audit timelines. The Company and AVM look forward to the planned merger during 2026 to continue and facilitate corporate growth of the combined entities. In addition, AVM has re-commenced its FDA Phase 2 Clinical Trial on relapsed and refractory Non- Hodgkins Lymphoma (“OPAL Trial”) for their small molecule immunomodulatory drug, AVM0703, working with Insight 68 an innovative Ai-driven platform company that drives digital transformation and scales to meet all corporate needs in clinical trials, scheduling, planning, manufacturing, and logistics. AVM expects to enroll an additional 7-10 more patients followed by submission to the FDA for review. AVM0703 has been administ…
Open exhibit ↗Current Report · Items 8.01, 9.01 · 8-K
AI TECHNOLOGY GROUP INC
AIPGOTCEQUITYCurrent
Other Events
Item 8.01 Other Events January 12, 2026, the Registrant and AVM Biotechnology, Inc. (“AVM”) issued a joint press release regarding the Registrant’s funding efforts and certain information regarding AVM. Section 9 - Financial Statements and Exhibits
Disclosure sections
Item 8.01Item 8.01 - Other Events
Item 8.01 Other Events
January 12, 2026, the Registrant and AVM Biotechnology, Inc. (“AVM”) issued a joint press release regarding the Registrant’s funding efforts and certain information regarding AVM.
Section 9 - Financial Statements and Exhibits